Neurorehabilitation News

A Philadelphia-area contract research organization has announced completion of a phase 1 clinical trial of CMX-2043, Ischemix Inc.’s novel, proprietary cytoprotective drug candidate to treat acute traumatic brain injury.

Young brain donors exposed to repetitive head impacts through contact sports displayed cognitive and neurobehavioral symptoms with or without a diagnosis of chronic traumatic encephalopathy, according to research from JAMA Neurology.

A clinical-stage biotechnology company announced that it has raised $150 million in funding to advance its neuromedicine platform.

Subcallosal cingulate gyrus deep brain stimulation was generally safe and significantly improved depressive symptoms in patients with treatment-resistant depression, with results sustained up to 7 years, according to research.

A Boston-area clinical stage drug discovery and development company announced $6 million in pre-Series B bridge financing to advance a novel cerebroprotectant therapeutic intended to treat a broad range of acute brain injuries.

Lumbar drainage following an aneurysmal subarachnoid hemorrhage was effective at reducing infarction and decreased rates of unfavorable neurological outcome at 6 months, according to data published in JAMA Neurology.

The FDA has approved once-daily Ingrezza capsules for adults with chorea associated with Huntington’s disease.

An Italian pharmaceutical company and a Boston-area biotechnology research firm announced a partnership to advance a novel blood-brain barrier-crossing platform technology for those with lysosomal storage disorders.

Traumatic brain injury in older adults was linked to alterations in self-perception, social life, ability to perform daily tasks and deterioration in quality of life for up to 5 years, according to research presented in Brain and Spine.

A Canadian firm has announced completion of a round of financing that netted almost $3.4 million for further commercialization of its cognitive performance software in clinics across the United States.